In this issue:
Repotrectinib in ROS1 fusion-positive NSCLC
Adding SBRT to standard care in oligoprogressive NSCLC/breast cancer
Docetaxel + ramucirumab after platinum chemotherapy + ICI in NSCLC
First-line durvalumab in advanced and metastatic ECOG 2 NSCLC
Perioperative toripalimab + chemotherapy for resectable NSCLC
Immune-related adverse events and survival in ICI-treated metastatic NSCLC
First-line osimertinib for NSCLC with uncommon EGFR mutations
Brain metastasis risk unchanged by anti-PD-L1 in extensive-stage SCLC
Antibiotics reduce survival in ICI-treated extensive-stage SCLC
Nivolumab + ipilimumab in real-world mesothelioma patients
Please login below to download this issue (PDF)